- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07951489
At Home Use of Noninvasive Vagus Nerve Stimulation Following TBI to Improve Cognition.
Randomized, Sham-controlled Clinical Trial Testing At-home Use of Noninvasive Vagus Nerve Stimulation After TBI
The purpose of this study is to evaluate whether individuals with TBI can comfortably and consistently use transcutaneous vagus nerve stimulation (tVNS) at home and to identify barriers that may affect participation. A secondary objective is to obtain preliminary data to examine whether at-home tVNS is associated with improvement in cognitive skills as well as any improvement in patient reported outcomes such as sleep, mood, or fatigue.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
This is a sham controlled pilot study to evaluate the feasibility and preliminary efficacy of remotely supervised, at-home delivery of tVNS in individuals with TBI during the post-acute recovery phase. Eligible participants will complete a 4-week tVNS intervention protocol at home. Mixed methods (quantitative and qualitative) will be used to evaluate outcomes. Eligible participants will be invited to initial baseline assessment and tVNS training session (Visit 1). Then, they will be randomly allocated to recieve either active or sham stimulation for the first two weeks of at-home administration period. They will then return for a min-intervention assessment (Visit 2). After the mid-intervention assessment, they will return home and recieve active stimulation for the remaining two weeks. Lastly, they will return to a post- intervention assessment (Visit 3). In the assessment sessions participants will complete tasks of set shifting and working memory, core executive functions, as well as complete surveys regarding fatigue, sleep, and overall quality of life.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Kathryn Magee, MHS., CCC-SLP/L, CBIS
- Numéro de téléphone: 312 238 6451
- E-mail: tvns_research@sralab.org
Sauvegarde des contacts de l'étude
- Nom: Shira Cohen-Zimerman, PhD
- Numéro de téléphone: 312 238 6450
- E-mail: tvns_research@sralab.org
Lieux d'étude
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60611
- Recrutement
- Shirley Ryan AbilityLab
-
Chicago, Illinois, États-Unis, 60611
- Pas encore de recrutement
- Shirley Ryan AbilityLab
-
Chercheur principal:
- Elliot Roth, MD
-
Contact:
- Kathryn Magee, MHS., CCC-SLP/L, CBIS
- Numéro de téléphone: 312 238 6451
- E-mail: tvns_research@sralab.org
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age 18-75 years Formally diagnosed with traumatic brain injury.
- Ability to independently use a keyboard.
- Ability to independently apply the electrode and adjust stimulation or have a designated caregiver available to be trained and assist with these tasks.
- Able to understand and communicate in English (according to clinical judgment).
- Able to independently provide consent to participate. -Able to come in person to Shirley Ryan AbilityLab in Chicago, IL for three visits over 5 weeks.
Exclusion Criteria:
- Acute medical issues requiring close physician or nursing monitoring. Bioelectrical implants, cerebral shunts, including pacemakers.
- Anyone with sore or diseased skin area in the ear
- Pregnancy or persons who are lactating.
- Cardiac arrhythmia.
- Epilepsy or seizure disorders.
- Significant gross or fine motor weakness.
- Significant, ongoing communication or comprehension impairments (such as aphasia) that would affect an individual's ability to complete the required assessments.
- Severely impaired memory retention
- Current major depression diagnosis.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Active Stimulation
Initial baseline assessment completed Day 0. Active stimulation using Tancutaneous Vagus Nerve Stimulation (tVNS) device , for atleast one hour a day for 14 days at home (Day1-14). A mid intervention assessment session completed on Day 15. Following that assessment, another two weeks (Day 16-29) of active stimulation at home followed by a post intervention assessment session. |
tVNS stimulation at home for atleast one hour a day for 4 weeks. |
|
Comparateur factice: Sham Stimulation
Initial baseline assessment completed Day 0. Sham stimulation using Tancutaneous Vagus Nerve Stimulation (tVNS) device, for atleast one hour a day for 14 days at home (Day1-14). A mid intervention assessment session completed on Day 15. Following that assessment, participant will switch to recieve active stimulation for the remaining 2 week at home (Day 16-29) followed by a post intervention assessment session. |
Participants will recieve two weeks of sham stimulation for atleast one hour a day, followed by 2 weeks of active stimulation for atleast one hour a day. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Recording the number of participant who completed at least 75% of the sessions out of the number of participants enrolled in the study.
Délai: Post Intervention Assessment Day 30
|
Post Intervention Assessment Day 30
|
|
Semi-structured interviews will collect feedback on perceived benefit, usability, logistical challenges, and barriers to adherence.
Délai: Post Intervention Assessment Session Day 30
|
Post Intervention Assessment Session Day 30
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
N-Back
Délai: Baseline Assessment: Day 0, Mid Intervention Assessment: Day 15, Post Intervention Assessment: Day 30
|
In the N-Back Task, participants are presented a series of visual stimuli. They are asking for each stimulus whether is matches a stimulus n-trials before. For example, in a 2-back task, in which the trials consist of letters, participants have to decide whether the current letter is the same as the letter in the trial n-2. We will use a computerized version of this task. |
Baseline Assessment: Day 0, Mid Intervention Assessment: Day 15, Post Intervention Assessment: Day 30
|
|
California Verbal Learning Test
Délai: Baseline Assessment: Day 0, Mid Intervention Assessment: Day 15, Post Intervention Assessment: Day 30
|
The California Verbal Learning Test evaluates the ability to encode, recall, and recognize verbally presented information across multiple learning trials and delayed recall conditions. Participants are read multiple lists of words and asked to recall specific words at different time allotments. |
Baseline Assessment: Day 0, Mid Intervention Assessment: Day 15, Post Intervention Assessment: Day 30
|
|
Trail Making A&B
Délai: Baseline Assessment: Day 0, Mid Intervention Assessment: Day 15, Post Intervention Assessment: Day 30
|
Trail Making Part A requires participant to draw a line between circles containing numbers in ascending order. Part B requires participants to alternate drawing a line between ascending letters and numbers. The key measures are the time required to complete and the number of errors made in Part A and Part B. The test measures various aspects of cognition including attention, visual search, motor coordination, reasoning, and task switching. |
Baseline Assessment: Day 0, Mid Intervention Assessment: Day 15, Post Intervention Assessment: Day 30
|
|
Conners Continuous Performance Test 3rd Edition
Délai: Baseline Assessment: Day 0, Mid Intervention Assessment: Day 15, Post Intervention Assessment: Day 30
|
CPT-3 is a computerized task requires of pressing the space bar on a computer keyboard after any letter is presented on the screen, except for the letter "X". This test lasts about 14 minutes. It measures several aspects of sustained attention, including inattention, impulsivity, and vigilance captured by measuring response styles, errors, and response times. |
Baseline Assessment: Day 0, Mid Intervention Assessment: Day 15, Post Intervention Assessment: Day 30
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- STU00226736
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .